title: Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).
abstract: An oral formulation based on poly (DL-lactide-co-glycolide) (PLG) microparticles was developed for delivery of antituberculous drugs. PLG entrapped antitubercular drugs when administered orally, were found to release the drugs in a sustained manner. This formulation was found to be stable in the acidic environment of gastric fluid whereas, in the intestinal fluid the drug release was obtained up to 20 days as indicated by in vitro studies. Pharmacokinetic analysis of the data revealed changes in C(max); AUC(o-alpha); t(1/2) (a) and t(1/2) (e) when drugs were given entrapped in PLG microparticles. Higher peak concentration, area under the concentration time curve and delayed elimination rate of entrapped drugs indicated the potential of PLG for effective treatment of tuberculosis. Further, work is being carried out to evaluate the chemotherapeutic efficacy of the antitubercular drugs encapsulated in PLG microspheres.
authors.affiliation: Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India.
authors.forename: Q
authors.initials: Q
authors.lastname: Ain
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: S K
authors.initials: SK
authors.lastname: Garg
authors.forename: G K
authors.initials: GK
authors.lastname: Khuller
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000493:pharmacokinetics; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D001672:Biocompatible Materials; D002214:Capsules; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D005260:Female; D006207:Half-Life; D007538:Isoniazid / Q000008:administration & dosage / Q000493:pharmacokinetics; D019344:Lactic Acid; D008297:Male; D051379:Mice; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011718:Pyrazinamide / Q000008:administration & dosage / Q000493:pharmacokinetics; D012293:Rifampin / Q000008:administration & dosage / Q000493:pharmacokinetics; D012995:Solubility
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D001672:Biocompatible Materials; D002214:Capsules; D003692:Delayed-Action Preparations; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D011718:Pyrazinamide; D019344:Lactic Acid; D007538:Isoniazid; D012293:Rifampin